At booth #115, Integer will spotlight its latest advancements in neuromodulation and next-generation miniaturized active implantable medical devices (AIMDs). These innovations are designed to ...

ReShape Lifesciences has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application on a new Diabetes Neuromodulation system utilizing its vagal nerve block ...

The FDA clears ProlivRx at-home neuromodulation for adjunctive major depressive disorder treatment in adults with inadequate antidepressant response.

The FDA has approved ProlivRx, the first prescription, home-based brain neuromodulation therapy, as an adjunctive treatment ...

ImagineHealth and Vivatronix partner to bring SpineX’s neuromodulation technology to global markets, enhancing recovery for neurological condition patients. Patients have been waiting for a solution ...

ReShape Lifesciences® announced the presentation of pre-clinical data for its innovative Diabetes Neuromodulation device at the Minnesota Neuromodulation Symposium. This device employs Hypoglycemia ...

Given the growing interest in non-invasive neuromodulation devices for the central nervous system, the Forum on Neuroscience and Nervous System Disorders hosted a public workshop on March 2-3, 2015 to ...

Prescription neuromodulation can be administered outside the clinic with physician oversig ...

Neurolief Inc., a medical device company focused on neuromodulation therapies for neuropsychiatric conditions, today ...

The battery-free percutaneous sacral neuromodulation system has comparable efficacy to published rates for traditional sacral neuromodulation devices. The US Food and Drug Administration (FDA) has ...

For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.